Journal article
Economic Analysis of Bisphosphonate Use after Distal Radius Fracture for Prevention of Hip Fracture
Archives of bone and joint surgery, v 5(6), pp 380-383
01 Nov 2017
PMCID: PMC5736886
PMID: 29299492
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Background: Osteoporosis is a common condition among the elderly population, and is associated with an increased risk of fracture. One of the most common fragility fractures involve the distal radius, and are associated with risk of subsequent fragility fracture. Early treatment with bisphosphonates has been suggested to decrease the population hip fracture burden. However, there have been no prior economic evaluations of the routine treatment of distal radius fracture patients with bisphosphonates, or the implications on hip fracture rate reduction.
Methods: Age specific distal radius fracture incidence, age specific hip fracture rates after distal radius fracture with and without risendronate treatment, cost of risendronate treatment, risk of atypical femur fracture with bisphosphonate treatment, and cost of hip fracture treatment were obtained from the literature. A unique stochastic Markov chain decision tree model was constructed from derived estimates. The results were evaluated with comparative statistics, and a one-way threshold analysis performed to identify the break-even cost of bisphosphonate treatment.
Results: Routine treatment of the current population of all women over the age of 65 suffering a distal radius fracture with bisphosphonates would avoid 94,888 lifetime hip fractures at the cost of 19,464 atypical femur fractures and $19,502,834,240, or on average $2,186,617,527 annually, which translates to costs of $205,534 per hip fracture avoided. The breakeven price point of annual bisphosphonate therapy after distal radius fracture for prevention of hip fractures would be approximately $70 for therapy annually.
Conclusion: Routine treatment of all women over 65 suffering distal radius fracture with bisphosphonates would result in a significant reduction in the overall hip fracture burden, however at a substantial cost of over a $2 billion dollars annually. To optimize efficiency of treatment either patients may be selectively treated, or the cost of annual bisphosphonate treatment should be reduced to cost-effective margins.
Metrics
Details
- Title
- Economic Analysis of Bisphosphonate Use after Distal Radius Fracture for Prevention of Hip Fracture
- Creators
- Suneel B. Bhat - Thomas Jefferson UniversityAsif M. Ilyas - Thomas Jefferson University
- Publication Details
- Archives of bone and joint surgery, v 5(6), pp 380-383
- Publisher
- Mashhad Univ Med Sciences
- Number of pages
- 4
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pediatrics
- Web of Science ID
- WOS:000423946200005
- Scopus ID
- 2-s2.0-85033368712
- Other Identifier
- 991021838156504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Orthopedics